vs

Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $1.1M, roughly 184.2× Insight Molecular Diagnostics Inc.). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -23.4%). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs 1.9%).

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

IMDX vs MYGN — Head-to-Head

Bigger by revenue
MYGN
MYGN
184.2× larger
MYGN
$209.8M
$1.1M
IMDX
Growing faster (revenue YoY)
MYGN
MYGN
+23.0% gap
MYGN
-0.4%
-23.4%
IMDX
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
1.9%
MYGN

Income Statement — Q4 2025 vs Q4 2025

Metric
IMDX
IMDX
MYGN
MYGN
Revenue
$1.1M
$209.8M
Net Profit
$-23.0M
Gross Margin
42.5%
70.0%
Operating Margin
-2057.5%
-2.7%
Net Margin
-2015.4%
Revenue YoY
-23.4%
-0.4%
Net Profit YoY
31.5%
EPS (diluted)
$-0.75
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMDX
IMDX
MYGN
MYGN
Q4 25
$1.1M
$209.8M
Q3 25
$260.0K
$205.7M
Q2 25
$518.0K
$213.1M
Q1 25
$2.1M
$195.9M
Q4 24
$1.5M
$210.6M
Q3 24
$115.0K
$213.3M
Q2 24
$104.0K
$211.5M
Q1 24
$176.0K
$202.2M
Net Profit
IMDX
IMDX
MYGN
MYGN
Q4 25
$-23.0M
Q3 25
$-10.9M
$-27.4M
Q2 25
$-9.7M
$-330.5M
Q1 25
$-6.7M
$-100.0K
Q4 24
$-33.5M
Q3 24
$-13.5M
$-22.1M
Q2 24
$-4.5M
$-36.7M
Q1 24
$-9.1M
$-26.0M
Gross Margin
IMDX
IMDX
MYGN
MYGN
Q4 25
42.5%
70.0%
Q3 25
53.5%
69.9%
Q2 25
67.6%
71.2%
Q1 25
62.0%
68.5%
Q4 24
40.0%
71.7%
Q3 24
43.5%
70.2%
Q2 24
48.1%
69.6%
Q1 24
25.6%
68.1%
Operating Margin
IMDX
IMDX
MYGN
MYGN
Q4 25
-2057.5%
-2.7%
Q3 25
-4249.2%
-11.3%
Q2 25
-1900.0%
-154.5%
Q1 25
-318.0%
-14.8%
Q4 24
-2262.9%
-18.6%
Q3 24
-11752.2%
-9.4%
Q2 24
-4453.8%
-17.3%
Q1 24
-5265.3%
-13.8%
Net Margin
IMDX
IMDX
MYGN
MYGN
Q4 25
-2015.4%
Q3 25
-4174.6%
-13.3%
Q2 25
-1880.7%
-155.1%
Q1 25
-312.0%
-0.1%
Q4 24
-2255.1%
Q3 24
-11733.0%
-10.4%
Q2 24
-4355.8%
-17.4%
Q1 24
-5186.9%
-12.9%
EPS (diluted)
IMDX
IMDX
MYGN
MYGN
Q4 25
$-0.75
$-0.09
Q3 25
$-0.34
$-0.29
Q2 25
$-0.30
$-3.57
Q1 25
$-0.26
$0.00
Q4 24
$-2.19
$-0.47
Q3 24
$-0.98
$-0.24
Q2 24
$-0.36
$-0.41
Q1 24
$-1.13
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMDX
IMDX
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$11.6M
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$-31.5M
$368.0M
Total Assets
$25.8M
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMDX
IMDX
MYGN
MYGN
Q4 25
$11.6M
$149.6M
Q3 25
$18.7M
$145.4M
Q2 25
$24.3M
$74.4M
Q1 25
$31.0M
$91.8M
Q4 24
$8.6M
$102.4M
Q3 24
$3.4M
$99.9M
Q2 24
$9.3M
$97.3M
Q1 24
$5.6M
$104.3M
Total Debt
IMDX
IMDX
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IMDX
IMDX
MYGN
MYGN
Q4 25
$-31.5M
$368.0M
Q3 25
$-9.2M
$372.8M
Q2 25
$1.1M
$388.1M
Q1 25
$10.2M
$704.9M
Q4 24
$-12.3M
$701.1M
Q3 24
$9.7M
$731.7M
Q2 24
$22.7M
$740.5M
Q1 24
$11.6M
$760.0M
Total Assets
IMDX
IMDX
MYGN
MYGN
Q4 25
$25.8M
$706.6M
Q3 25
$43.9M
$728.1M
Q2 25
$50.5M
$677.3M
Q1 25
$60.4M
$1.0B
Q4 24
$35.1M
$1.0B
Q3 24
$70.2M
$1.1B
Q2 24
$74.7M
$1.1B
Q1 24
$71.0M
$1.1B
Debt / Equity
IMDX
IMDX
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMDX
IMDX
MYGN
MYGN
Operating Cash FlowLast quarter
$-5.5M
$10.6M
Free Cash FlowOCF − Capex
$-7.0M
FCF MarginFCF / Revenue
-616.7%
Capex IntensityCapex / Revenue
129.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMDX
IMDX
MYGN
MYGN
Q4 25
$-5.5M
$10.6M
Q3 25
$-4.5M
$21.1M
Q2 25
$-6.3M
$-13.6M
Q1 25
$-5.9M
$-16.3M
Q4 24
$-5.4M
$6.6M
Q3 24
$-5.5M
$700.0K
Q2 24
$-6.0M
$2.6M
Q1 24
$-3.8M
$-18.6M
Free Cash Flow
IMDX
IMDX
MYGN
MYGN
Q4 25
$-7.0M
Q3 25
$-5.6M
Q2 25
$-6.6M
Q1 25
$-6.2M
Q4 24
$-5.6M
Q3 24
$-5.6M
Q2 24
$-6.2M
Q1 24
$-3.9M
FCF Margin
IMDX
IMDX
MYGN
MYGN
Q4 25
-616.7%
Q3 25
-2135.4%
Q2 25
-1279.5%
Q1 25
-288.4%
Q4 24
-374.5%
Q3 24
-4884.3%
Q2 24
-5931.7%
Q1 24
-2189.8%
Capex Intensity
IMDX
IMDX
MYGN
MYGN
Q4 25
129.9%
Q3 25
403.8%
Q2 25
67.4%
Q1 25
14.4%
Q4 24
14.4%
Q3 24
75.7%
Q2 24
183.7%
Q1 24
13.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons